Online ISSN: 1949-2553
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

Decoding the Mechanism Behind MCL-1 Inhibitors: A Pathway to Understanding MCL-1 Protein Stability

News

June 28, 2023
PRESS RELEASE: On June 21, 2023, a new editorial paper was published in Oncotarget, entitled, “Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability.” continue reading »

DPDT Anticancer Activity in Human Colon Cancer HCT116 Cells

News

June 26, 2023
PRESS RELEASE: On June 21, 2023, a new research paper was published in Oncotarget, entitled, “Diphenyl ditelluride anticancer activity and DNA topoisomerase I poisoning in human colon cancer HCT116 cells.” continue reading »

Targeting GITR in cancer immunotherapy – there is no perfect knowledge

News

June 21, 2023
PRESS RELEASE: On June 19, 2023, a new research perspective was published in Oncotarget, entitled, “Targeting GITR in cancer immunotherapy – there is no perfect knowledge.” continue reading »

Metformin’s Role in Preventing Metabolic Syndrome during Androgen Deprivation Therapy: A Phase II Study

News

June 20, 2023
PRESS RELEASE: On June 19, 2023, a new research paper was published in Oncotarget, entitled, “Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.” continue reading »

New Study Reveals Genetic Risk Factors for Cancer in Saudi Arabia

Oncotarget

June 16, 2023
In a new study, researchers found that 38.4% of a cohort in Saudi Arabia carried pathogenic variants linked to hereditary cancer risk. continue reading »